You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
On July 13, President Clinton announced the 10 centers chosen to replicate the Edmonton Protocol.
The $5 million Edmonton Protocol replication will begin this fall and will be overseen by the Immune Tolerance Network (ITN), a research program jointly funded by the National Institutes of Health (NIH) and the Juvenile Diabetes Foundation (JDF). As part of the replication, approximately 40 patients will receive islet transplants in the next 18 months through the ITN clinical trials.
"This is an important moment for people with diabetes," said Mary Tyler Moore, international chairman of the JDF. "We greatly applaud the Administration's commitment to diabetes research and are proud to partner with the NIH on replicating the Edmonton Protocol for human islet transplantation through the Immune Tolerance Network."
Bringing the Cure Closer to Home
James Shapiro, MBBS, BMed, a transplant surgeon for the Edmonton Protocol team, told DIABETES HEALTH he is pleased with the announcement.
"I am thrilled that the proposed study, together with the preliminary extraordinary results from the Edmonton Protocol, was considered important enough to gain the attention of the U.S. President," said Shapiro. "I'd be even more thrilled if the overall results of the multi-center study match up to the success we have seen in Edmonton. This will bring islet transplantation as a cure so much closer to all patients with diabetes."
10 People Off Insulin After One Year
The Edmonton Protocol research team recently published its findings in The New England Journal of Medicine. Shapiro and colleagues at the University of Alberta in Edmonton transplanted islets in 10 people with type 1 diabetes. In previous studies, only eight percent of islet-transplant recipients have remained off insulin for one year.
The Edmonton Protocol is the first study in which 100 percent of islet-transplant recipients were completely insulin-independent after one year. The keys to the success of the Edmonton Protocol are a new anti-rejection drug combination, the avoidance of steroids and the delivery of sufficient islets.
According to the JDF, only "brittle" type 1 diabetes patients, ranging from 18 to 65 years of age, who are unable to properly control their sugars with even the most rigid insulin schedule, are eligible to participate. Patients must also suffer from one of the following:
People with type 2 diabetes and children are not eligible for enrollment in the trial. In addition, type 1s with severe cardiac disease, active or recent history of substance abuse (including smoking), insulin requirements greater than 0.7 U/kg per day or active infection (including hepatitis B or C, HIV or TB) are not eligible to participate.
U.S. residents who meet the requirements who are interested in participating are asked to visit the ITN Web site at www.immunetolerance.org or call the ITN Patient Referral Hotline at (773) 834-5341.
0 comments - Sep 1, 2000
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.